Lyric Pharmaceuticals Announces $20.4M Series A Funding Round

SOUTH SAN FRANCISCO, CA, February 26, 2015Lyric Pharmaceuticals Inc. today announced the initial closing of a Series A financing round totaling $20.4 million. The financing, co-led by RiverVest Venture Partners, Santé Ventures and Third Point Ventures, includes participation by Aperture Venture Partners.

Read More

Otonomy Submits New Drug Application to the FDA for AuriPro(TM)

SAN DIEGO, Feb. 26, 2015 (GLOBE NEWSWIRE) Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of AuriProTM as a treatment of middle ear effusion in pediatric patients undergoing tympanostomy tube placement (TTP) surgery.

Read More

Neuros Medical Enrolls First Patients in Pivotal Study for Post-Amputation Pain

Cleveland, OH, January 28, 2015– Neuros Medical, Inc., a medical device company, announced it has enrolled the first patients in its pivotal clinical trial to evaluate the Company’s patented Altius® System High Frequency Nerve Block technology for the management of intractable limb pain of amputees.

Read More

Big year: RiverVest turns in strong 2014, eyes 2015 growth

By:  Brian Feldt, Reporter
St. Louis Business Journal

December 26, 2014


RiverVest Venture Partners, the Clayton-based venture capital firm, has for several years been considered one of the leading investing firms in the nation when it comes to medical technology.

This year may be its best campaign yet.

RiverVest exited a dozen portfolio companies since 2011, returning $290.5 million to the firm, or 3.5 times the dollars invested in those companies ($83 million).  Read more.

Source: St. Louis Business Journal

Read More